Target intelligence / Profile preview

Canine parvovirus VP2 capsid protein (VP2)

Target
VP2
Molecular classification
Viral protein, Capsid protein, Other
01

Overview

Canine parvovirus VP2 capsid protein is the major structural component of the canine parvovirus (CPV-2) capsid, constituting approximately 90% of the viral shell. It plays a critical role in viral pathogenesis by mediating attachment to host cell receptors, specifically the canine transferrin receptor type-1 (TfR), which is essential for viral entry and subsequent replication in rapidly dividing host cells such as intestinal enterocytes and bone marrow cells. Mutations in the VP2 protein drive the antigenic evolution of CPV-2 variants (such as CPV-2a, CPV-2b, and CPV-2c) and determine host range.

As a therapeutic target, VP2 is neutralized by the monoclonal antibody anivovetmab (marketed under the trade name Trutect, formerly known as CPMA), which binds to the capsid protein to block viral entry and prevent hemorrhagic gastroenteritis and mortality in infected dogs. Additionally, VP2 serves as the primary antigen in diagnostic assays, such as fecal antigen ELISA and lateral flow tests, and is a key component in vaccine development, including virus-like particles (VLPs) designed to elicit protective humoral immunity.

Other names
Canine parvovirus antigenCanine parvovirus major capsid protein VP2CPV VP2CPV-2 VP2Canine parvovirus capsid protein VP2
02

Mechanism of action

Neutralization of canine parvovirus by binding to the VP2 capsid protein, preventing viral attachment and entry into host enterocytes.

03

Biological functions

Viral entryHost cell attachmentViral capsid assemblyOther
04

Disease associations

InfectionOther
05

Safety considerations

Infusion-related reactionsAnaphylaxisInterference with active immunization (modified-live virus vaccines)
06

Interacting drugs

Anivovetmab
07

Biomarkers

Fecal canine parvovirus antigenFecal CPV-2 PCR

Beyond the preview

Go deeper on Canine parvovirus VP2 capsid protein (VP2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Canine parvovirus VP2 capsid protein (VP2).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call